OMF Australia Marks 4th Anniversary: Progress, Hope, and Our Path Forward
We recently marked a significant milestone – the fourth anniversary of Open Medicine Foundation (OMF) Australia – with a special gathering in Melbourne. Hosted at the historic Cranlana House, the event brought together the brilliant minds behind our research, board members, and key partners. It was a particularly meaningful occasion as we welcomed OMF Founder […]
New Publication: Harnessing AI and Big Data for Precision Medicine in ME/CFS and Long COVID
Big Data and Artificial Intelligence (AI) have great potential to advance precision medicine for ME/CFS and Long COVID. Dr. Chris Armstrong and his colleagues have recently published a paper titled “Machine learning and multi-omics in precision medicine for ME/CFS”. In this review, the team explores how machine learning and multi-omics (genomics, transcriptomics, proteomics, and metabolomics) […]
New Protocol Paper: Investigating ME/CFS Impact and Biological Mechanisms in Adolescents
The underlying biological mechanisms for ME/CFS remain unclear and have rarely been investigated in the adolescent population, despite this period representing an age peak in the overall incidence. We’re pleased to share the ‘Serial Paediatrics Omics Tracking in Myalgic Encephalomyelitis (SPOT-ME)’ protocol paper from the Melbourne ME/CFS Collaboration. From the Desk of Dr. Chris ArmstrongMelbourne […]
The Life Improvement Trial
The Life Improvement Trial (LIFT) Study AIM The Life Improvement Trial (LIFT) aims to investigate two drugs, separately and in combination, Pyridostigmine (commonly known as Mestinon) and Low-Dose Naltrexone (LDN), for efficacy and to research the difference between responders and non-responders. LEAD INVESTIGATORS David Systrom, MD Jonas Bergquist, MD/PhD Donna Felsenstein, MD Wenzhong Xiao, PhD […]
Announcement!!! A New Large-Scale ME/CFS Biomarker Study (BioQuest)!
We are excited to announce that, thanks to two very generous grants, we have successfully secured $800,000—one-third of our goal—that will allow us to initiate a large-scale ME/CFS biomarker study (BioQuest)! The Heart of the Matter OMF has received funding to start an ME/CFS biomarker study, called BioQuest. The goal of BioQuest is to identify […]
Groundbreaking Nature Publication: Dr. Armstrong’s Metabolomics Study Advances ME/CFS Diagnosis
Today, we are excited to share a new publication by Christopher Armstrong, PhD, & colleagues: “Discriminating ME/CFS and Comorbid Conditions Using NMR Metabolomics in UK Biobank.” The Heart of the Matter The OMF Melbourne ME/CFS Collaboration recently published an article on their project using metabolomics to identify ME/CFS. The team analysed metabolomics data on over […]
Video Update: Linking Brain Blood Flow, Neuroinflammation, Metabolism, and Hormones in ME/CFS, POTS, and Long COVID
Linking Brain Blood Flow, Neuroinflammation, Metabolism, and Hormones in ME/CFS, POTS, and Long COVID Watch Now The Heart of the Matter Neuroinflammation, altered cerebral blood, and dysregulated hormones have all been separately observed in ME/CFS in prior research. Dr. Armstrong and his team at OMF’s Melbourne ME/CFS Collaboration have designed a study to examine the […]
Studying CSF to further reveal pathogenesis mechanisms in ME/CFS
The goal of this research is to reveal more information about the role of immunology and neuroinflammation in ME/CFS, and the underlying mechanisms of related pathogenesis that takes place.
Multi-Omic Approaches to Solve Post-Acute COVID-19 (MOSAIC)
The purpose of this study is to facilitate early detection of ME/CFS in people with Long COVID and better understand disease progression.
Life Improvement Trial (LIFT) has officially begun!
The Life Improvement Trial (LIFT) has officially begun! Conducting a proper clinical trial and ensuring all logistics are set up takes time, so we are excited to share that Open Medicine Foundation’s Life Improvement Trial (LIFT) has officially launched. Recruitment and screening began in August and the first participants have now been enrolled. What is […]
